Human papillomavirus vaccination for the prevention of cervical neoplasia: Is it appropriate to vaccinate women older than 26?

Medical Journal of Australia

Volumn 188, Issue 4, 2008, Pages 238-242

  Skinner, S Rachel ^a,b   Garland, Suzanne M ^c,d   Stanley, Margaret A ^e   Pitts, Marian ^f   Quinn, Michael A ^c,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GARDISIL; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ARTICLE; AUSTRALIA; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INFECTION RISK; PAPANICOLAOU TEST; PREVALENCE; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; WOMEN'S HEALTH; ADULT; AGE; AGE DISTRIBUTION; AGED; IMMUNOLOGY; MIDDLE AGED; REVIEW; UTERINE CERVIX TUMOR; VIRUS INFECTION;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SEXUAL BEHAVIOR; UTERINE CERVICAL NEOPLASMS;

EID: 42449119427     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb01593.x     Document Type: Article

References (41)

1. Clifford G, Franceschi S, Diaz M, et al. HPV type-distribution in women with and without cervical neoplastic disease. Vaccine 2006; 24 Suppl 3: S26-S34.
2. Vandepapeliere P, Barrasso R, Meijer CJ, et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005; 192: 2099-2107.
3. Clifford GM, Rana RR, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-1164.
4. Regan DG, Philp DJ, Hocking JS, Law MJ. Modelling the impact of a vaccine on HPV 16 transmission in Australia. Sex Health 2007; 4: 147-163.
5. Kulasingam S, Connelly L, Conway E, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Heath 2007; 4: 165-175.
6. Australian Institute of Health and Welfare. Cervical screening in Australia 2004-2005. Canberra: AIHW, 2007. http://www.aihw.gov.au/ publications/index.cfm/title/10457 (accessed Jan 2008).
7. Bosch F, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.
8. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218-226.
9. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24 Suppl 1: S1-S15.
10. Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24 Suppl 1: S16-S22.
11. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84.
12. Ho GY, Studentsov Y, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004; 13: 110-116.
13. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13: 324-327.
14. De Jong A, van Poelgeest MI, van der Hulst JM, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64: 5449-5555.
15. International Agency for Research on Cancer. Globocan 2002 [database]. Lyon: IARC, 2005. http://www-dep.iarc.fr (accessed Jan 2008).
16. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer in Australia 2001. AIHW cancer series no. 28. Canberra: AIHW, 2004.
17. Garland S. Can we really beat cervical cancer? Med J Aust 2003; 178: 647-650.
18. Bosch FX, de Sanjosé S. Chapter 1. Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003; (31): 3-13.
19. Garland SM, Brotherton J, Condon J, et al. Human papillomavirus genotype prevalence in Australian women (Indigenous, non-Indigenous, urban, rural populations). International Papillomavirus Conference; 2007 Nov 2-9; Beijing, China.
20. de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 453-459.
21. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677-2684.
22. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1808-1816.
23. Graham JE, Christian LM, Kiecolt-Glaser JK. Stress, age and immune function: toward a lifespan approach. J Behav Med 2006; 29: 389-400.
24. García-Piñeres AJ, Hildesheim A, Herrero R, et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res 2006; 66: 11070-11076.
25. Munoz N, Mendez F, Posso H, et al. Incidence, duration and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077-2087.
26. Sellors J, Karwalajtys TL, Kaczorowshi J, et al; Survey of HPV in Ontario Women Group. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003; 168: 421-425.
27. Franco E, Villa LL, Sobrinho JP, et al. Epidemiology of acquistion and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 1415-1423.
28. Grainger MJ, Seth R, Guo L, et al. Cervical human papillomavirus screening among older women. Emerg Infect Dis 2005; 11: 1680-1685.
29. Johnson A, Mercer CH, Erens B, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001; 358: 1835-1842.
30. de Visser RO, Smith AM, Rissel CE, et al. Sex in Australia: heterosexual experience and recent heterosexual encounters among a representative sample of Australian adults. Aust N Z J Public Health 2003; 27: 146-154.
31. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24 Suppl 3: S52-S61.
32. Drumright LN, Gorbach PM, Holmes KK. Do people really know their sex partners? Concurrency, knowledge of partner behavior, and sexually transmitted infections within partnerships. Sex Transm Dis 2004; 31: 437-442.
33. Lehtinen M, Kaasila M, Pasanen K, et al. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 2006; 119: 2612-2619.
34. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002; 186: 1396-1402.
35. Wang S, Schiffman M, Shields TB, et al. Seroprevalence of human papillomavirus- 16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003; 80: 1248-1254.
36. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-1868.
37. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170.
38. Garland SM, Hernandez-Avila M, Wheeler-CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943.
39. Harper DM, Franco EL, Wheeler C, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow up from a randomised controlled trial. Lancet 2006; 367: 1247-1255.
40. Schwarz TF, Dubin GO; HPV Vaccine Study Investigators for Adult Women. An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old. American Society of Clinical Oncology Annual Meeting; 2006 Jun 2-6; Atlanta, Ga. Abstract 1008. http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview= abst_detail_view&confID=40&abstractlD=34377 (accessed Jan 2008).
41. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-5583.